Authors

Latest:

Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIs

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

Harikrishna Nakshatri, BVSc, PhD

Latest:

Dr Nakshatri on the Investigation of TONSL in Breast Cancers

Harikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.

Harold A. Harvey, MD

Latest:

Dr. Harvey Discusses Preventing Breast Cancer

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

Harold Burstein, MD, PhD

Latest:

Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Harold J. Burstein, MD, PhD

Latest:

Dr. Burstein on the Treatment Landscape of HER2+ Breast Cancer

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the treatment landscape of HER2-positive breast cancer.

Harold J. Burstein, MD, PhD, Dana-Farber

Harold J. Burstein, MD, PhD, Dana-Farber&nbsp

Harold J. Burstein, MD, PhD, Dana-FarberÂ

Harold J. Burstein, MD, PhD, Harvard Medical School

Harold P. Freeman, MD

Latest:

Dr. Freeman Describes Patient Navigation

Dr. Harold P. Freeman from Ralph Lauren Center for Cancer Care and Prevention Describes Patient Navigation

Harriet Kluger, MD

Latest:

Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

Harry Erba, MD, PhD

Harry P. Erba, MD, PhD, is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute

Latest:

Dr Erba on the FDA Approval of Ziftomenib in NMP1-Mutant Relapsed/Refractory AML

Harry Erba, MD, PhD, discusses the significance of the FDA approval of ziftomenib in NMP1-mutant, relapsed/refractory acute myeloid leukemia.

Harry P. Erba, MD, PhD, Duke Cancer Institute

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Harry Erba, MD, PhD, Duke University

Harry Erba, MD, PhD, University of Alabama

Harry Erba, MD, PhD, University of Alabama at Birmingham

Harry H. Yoon, MD

Latest:

A Look Towards the Future of ESCC

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Harry P. Erba, MD, PhD, Duke University School of Medicine

Latest:

The Role of Venetoclax for Treatment of AML

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Harry P. Erba, MD, PhD, Duke University

Harry P. Erba, MD, PhD, UAB